Meta reserved up to 100 GWh from Palo Alto’s Noon Energy to back up AI data centers. The project begins with a 25 MW pilot aimed for completion in 2028.

Framingham startup Tortugas raised $106M to advance four Phase 2 brain‑drug programs, including schizophrenia and tinnitus candidates licensed from Eisai and Hansoh. The funds will bankroll completion of key midstage trials.

More than 100 civic, business and philanthropic leaders met at Focus: HOPE to unpack Detroit Future City's new 'Tech Tomorrow' report and map equity-first tech growth. The report forecasts 20,000 jobs and $6.8B in wages if investments hold.

SpaceX said Tuesday it can buy San Francisco’s Cursor for $60 billion or pay $10 billion for a partnership. The move ties Musk’s AI push to a startup that has raised billions and rapidly grown revenue.

Tukwila‑based Avalanche Energy won a roughly $5.2M DARPA award to build micro "nuclear batteries," a near‑term step toward its goal of compact fusion power. The work pairs government money with recent VC funding and test‑facility expansion.

Taiwan’s JelloX Biotech will work with Mayo Clinic at Discovery Oasis, bringing AI 3D pathology to Phoenix’s growing bioscience corridor.

Japanese materials firm Resonac opened the U.S.'s first advanced semiconductor packaging R&D center in Union City, joining a US‑JOINT consortium to speed AI chip development.

Meta will install software to log employees' mouse movements and keystrokes to train AI agents, prompting fresh privacy concerns and regulatory scrutiny.

Gov. Greg Abbott and Michael and Susan Dell will join UT leaders Tuesday at a West Braker Lane event. University and state officials are expected to attend; specifics remain unclear.

UT Austin, UTSA and Baylor are moving AI into core computer‑science classes as software hiring cools and many students delay the job market for extra training.

Chevy Chase’s Blue Energy raised $380M to prefab shipyard‑built nuclear plants and says the first 1.5GW Texas project could start construction in Q3 2026 with a gas‑to‑nuclear plan.

London-based Synthesia is opening a downtown Austin office and expects dozens of hires by year end as it scales U.S. operations. The move follows a major funding round.

The European Commission authorized Moderna’s mCOMBRIAX for adults 50+, giving the Cambridge company a key commercial win while U.S. approval remains unsettled.